STOCKHOLM, Sept. 9, 2018 /PRNewswire/ -- Xspray Pharma AB (Nasdaq First North: XSPRAY) today announces positive data from a clinical bioequivalence study with the company's lead product candidate HyNap-Dasa. The
Growth Capitalist (https://growthcapitalist.com/2018/09/xspray-pharma-announces-positive-clinical-data-for-its-lead-product-candidate-hynap-dasa/)
STOCKHOLM, Sept. 9, 2018 /PRNewswire/ -- Xspray Pharma AB (Nasdaq First North: XSPRAY) today announces positive data from a clinical bioequivalence study with the company's lead product candidate HyNap-Dasa. The